Sixteen years of treatment with pasteurized human clotting factor concentrates in children and adolescents: A pharmacosurveillance investigation comprising 727 patient years

Seminars in Thrombosis and Hemostasis

Volumn 28, Issue SUPPL. 1, 2002, Pages 63-73

  Muntean, Wolfgang ^a   Zenz, Werner ^a   Falger, Jutta ^a   Male, Christoph ^a   Streif, Werner ^a   Wank, Johann ^a   Schwarz, Rudolf ^a   Schmitt, Klaus ^a   Kurnik, Peter ^a   Zwiauer, Karl ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BEHRING HS; BERIATE HS; BLOOD CLOTTING FACTOR 13 CONCENTRATE; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9; HAEMATE;

ADOLESCENT; AUSTRIA; BLOOD CLOTTING FACTOR 13 DEFICIENCY; BLOOD COMPONENT THERAPY; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; FEMALE; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; MALE; PASTEURIZATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIRUS TRANSMISSION; VON WILLEBRAND DISEASE;

EID: 0036232550     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-30198     Document Type: Conference Paper

References (45)

1. Modern treatment of hemophilia: From the shadows towards the light
2. Safety of coagulation factor concentrates
3. Viral safety of plasma-derived factor VIII und IX concentrates
4. Absence of anti-human immunodeficiency virus types I and II seroconversion after the treatment of haemophilia A or von Willebrand disease with pasteurized factor VIII concentrate
5. Low risk for hepatitis C in hemophiliacs given a high-purity, pasteurized factor VIII concentrate
6. Hepatitis C-antikörper bei kindern und jugendlichen mit angeborenen gerinnungsstörungen
7. Human parvovirus B 19 in clotting factor concentrates: B 19 DNA detection by the nested polymerase chain reaction
8. Human parvovirus B19 infection in hemophiliacs first transfused with two high-purity, virally attenuated factor VIII concentrates
9. Parvovirus B19 is frequently present in recombinant coagulation factor VIII products
10. Seroprevalence of parvovirus B19, cytomegalovirus, hepatitis A virus and hepatitis E virus antibodies in hemophiliacs treated exclusively with clotting-factor concentrates considered safe against human immunodeficiency and hepatitis C viruses
11. Factor VIII inhibitors
12. A multicenter study of recombinant factor VIII (Recombinante®): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A
13. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII
14. Incidence of factor VIII inhibitor development in hemopilia A patients treated with less pure plasma derived concentrates
15. Incidence of inhibitors in haemophiliacs. A review of the literature
16. The natural history of factor VIII inhibitors in patients with hemophilia A: A national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors
17. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate
18. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands
19. Viral safety and inhibitor development associated with monoclonal antibody-purified FVIIIC
20. Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate
21. Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII
22. Effects of chronic factor VIII substitution on immune parameters in HIV seronegative haemophiliacs: A comparison between cryoprecipitate and factor VIII concentrate
23. Progressive change in lymphocyte distribution and degree of hypergammaglobulinemia with age in children with hemophilia
24. Effect on lymphocyte subsets of clotting factor therapy in human immunodeficiency virus-1-negative congenital clotting disorders
25. Immune status of HIV and HCV negative haemophiliacs treated with intermediate-purity factor VIII concentrates
26. High versus ultra-high purity factor VIII concentrate therapy: Prospective evaluation of immunological and clinical parameters in HIV seronegative and seropositive hemophiliacs
27. Effects of factor VIII concentrates on the immune system in hemophilic patients
28. Influence of factor VIII, factor IX and immunoglobulin preparations on proliferative responses of mitogen-activated lymphocytes
29. The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virus-infected hemophiliacs: A randomized, prospective, two-year comparison with an intermediate purity concentrate
30. Purity of factor VIII concentrates and serial CD4 counts
31. Proceedings: A more uniform measurement of factor VIII inhibitors
32. The signal strengthening power of statistics: A demonstration of regression with unknown model domain in statistics and pharmacoeconomics
33. Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations
34. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses
35. Hepatitis A in western Austria, the epidemiological situation before the introduction of active immunisation
36. Parvovirus B19 infection
37. The prevalence of antibody to parvovirus B19 in hemophiliacs and in the general population
38. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization
39. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A
40. Hypoplastic anemia in a hemophiliac first infused with a solvent/detergent treated factor VIII concentrate: The role of human B19 parvovirus
41. Life-threatening human parvovirus B19 infection in immunocompetent hemophilia
42. High titer inhibitors in severe haemophilia A. A meta analysis based on eight long-term follow-up studies concerning inhibitors associated with crude or intermediate purity factor VIII products
43. The natural history of the immune response to exogenous factor VIII in severe haemophilia A
44. T-cell alterations in hemophiliacs treated with commercial clotting factor concentrates